Houston, TX, (August 2, 2005) Cytogenix, Inc. (CYGX: OTC: BB)
CytoGenix, Inc. (CYGX: OTC: BB) and Aldevron announced today a collaboration to conduct experiments with a DNA vaccine produced using CytoGenix proprietary DNA production process.
CytoGenix scientists will prepare the synthetic DNA vaccine designed to stimulate an immune response to a Hepatitis B Surface antigen. Aldevron will test the activity of this DNA vaccine in models established and validated by Aldevron scientists. Aldevron will conduct the experimental evaluation of the DNA vaccine with the company's proprietary Genetic Immunization and Antibody (GIA(tm)) technology.
Dr. Malcolm Skolnick, President and CEO commented, "This mutually beneficial corporate collaboration will provide important data key to the future of DNA vaccine research and development. We look forward to working with Aldevron on this seminal project."
Michael Chambers, President and CEO of Aldevron stated, "CytoGenix has developed a technology capable of greatly reducing the cost of DNA vaccine production. We are excited to evaluate plasmid-DNA produced with this technology via our GIA(tm) platform. Furthermore, we expect these studies will show equal or greater levels of immune response from the CytoGenix synthetic DNA vaccines when compared to first generation plasmid DNA constructs."
About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology.
About Aldevron: With facilities in the United States and Europe, Aldevron offers products and services to the DNA vaccine and gene therapy community. These include contract bio-manufacturing, genetic immunization and antibody production, and a complete line of gene therapy plasmids. More information can be found at http://www.aldevron.com.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission.
Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
Contact: CytoGenix, Inc., Communications Director - Juan Ferreira, (800) 677-5707
